COMMUNIQUÉS West-GlobeNewswire

-
Arrayit Corporation Retains Top Credentialing Company to Accelerate Allergy Testing Services Reimbursement from Major Healthcare Payors
06/05/2019 -
Zealand Pharma hosts conference call on May 16 at 4 pm CET (10 am EST) to present first quarter results for 2019
06/05/2019 -
Share buy-back week 18/2019
06/05/2019 -
Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obtaining Preparatory Documents for the General Meeting
06/05/2019 -
Assemblée Générale Mixte du 24 mai 2019 - Modalités de mise à disposition des documents préparatoires à l’Assemblée
06/05/2019 -
LIDDS: Liproca® Depot open label extension study indicates longer treatment intervals
06/05/2019 -
Reminder: C-RAD Web Presentation Interim Report Q1 2019
06/05/2019 -
Herantis Pharma publishes newsletter for March-April
06/05/2019 -
ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors
06/05/2019 -
ERYTECH propose la nomination du Dr. Jean-Paul Kress au poste de Président du Conseil d’administration
06/05/2019 -
Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019
06/05/2019 -
Nicox : Présentation sur l’étude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters à la conférence ASCRS 2019
06/05/2019 -
Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s
06/05/2019 -
Addex to Present During the Swiss Biotech Day
06/05/2019 -
Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
05/05/2019 -
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
05/05/2019 -
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting
05/05/2019 -
Emerald Health Therapeutics annonce les résultats financiers du quatrième trimestre et de l’exercice 2018; faits saillants entourant la croissance des ventes au T1 2019
04/05/2019 -
RavenQuest Awarded its First Cannabis Sales License from Health Canada
03/05/2019
Pages